Author: Editor

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Srdan Verstovsek discusses therapeutic insights into the clonal evolution of myeloproliferative neoplasms to accelerate of blastic phase. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Claire Harrison outlines her approach to the management of myelofibrosis. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Hans Michael Kvasnicka discsuses myelofibrosis marrow morphology and the key takeaways from the WHO 2016 diagnostic update. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities resulting from the utilization of experimental therapeutics for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal use of lanalidomide as therapy for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Norbert Gattermann discusses iron chelation therapy for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Eva Hellström-Lindberg outlines her approach to the management of myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Austin G. Kulasekararaj discusses the difference between hypocellular MDS and aplastic anemia, with emphasis on diagnosis and therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view on the current and future use of JAK inhibitors for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology Also Recommended: Myelofibrosis Danazol vs Momelotinib a JAK inhibitor© 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that circulating tumor DNA is ready to guide adjuvant therapy in colon cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that observation without surgery is not reasonable for rectal cancers that have achieved a clinical CR. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Julio Garcia-Aguilar argues that observation without surgery is reasonable for rectal cancers that have achieved a clinical CR. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz discusses the difference in the sided-ness of colon cancers and whether biomarkers or biology are more relevant in determing therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that immunotherapy is the optimal treatment for refractory colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that TAS-102 or regorafenib are the optimal treatment for refractory colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR antibodies are mandatory targeted therapy for RAS/BRAF wild-type left sided colon cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-type left sided colon cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg provides an update in the management of neuroendocrine cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update to advances in liquid biopsies and their relevance to the treatment of GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

Dr. Aly-Khan Lalani, MD highlights a study he presented at ESMO 2017 about the usefulness Neutrophil-to-lymphocyte ratio (NLR) and how they might be a good prognosticator in mRCC. Below is an overview of the study and it’s findings. RESULTS: Table 2. Association of NLR at baseline, at 6-weeks, and change at week 6 (±2) with treatment outcomes in multivariable Cox and Logistic regression models BACKGROUND: Inflammation is a hallmark of solid tumors, where neutrophilia occurs as an inflammatory response and may suppress the cytolytic activity of immune cells such as lymphocytes, natural killer cells, and activated T cells1 Elevated NLR…

Dr. Aly-Khan Lalani, MD gives an overview of the advancements in Kidney Cancer presented at ESMO 2017 including the Cabosun and Checkmate 214 trial results. CABOSUN Results: The Alliance for Clinical Trials in Oncology as part of Exelixis collaboration with the National Cancer Institutes Cancer Therapy Evaluation Program (NCI-CTEP). The data presented at ESMO 2017 included the analysis from a blinded independent radiology review committee (IRC), which confirmed the primary efficacy endpoint results of investigator-assessed progression-free survival (PFS), as well as an updated investigator-assessed analysis. Per the IRC analysis, cabozantinib demonstrated a clinically meaningful and statistically significant 52 percent reduction…

Dr. Aly-Khan A. Lalani, MD discusses the impact of Neutrophil-to-lymphocyte ratio (NLR) in mRCC and it’s effect on outcomes. BACKGROUND: Inflammation is a hallmark of solid tumors, where neutrophilia occurs as an inflammatory response and may suppress the cytolytic activity of immune cells such as lymphocytes, natural killer cells, and activated T cells1 Elevated NLR is associated with worse outcomes in several malignancies, including metastatic renal cell carcinoma (mRCC) patients treated with oral tyrosine kinase inhibitors (VEGF-TKIs)2 However, the utility of NLR in mRCC patients treated with conventional immune checkpoint blockade is not well characterized OBJECTIVES: To evaluate the association…

During this segment from the Living Well series, Dr. Bart Scott, breaks down whats occurring at a cellular level with an essential thrombocythemia (ET) diagnosis. Dr. Scott also discusses physical reactions patients may experience, common mutations seen in ET, and treatment options available to combat the disease. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Although essential thrombocythemia (ET) is generally thought of as a disease that only affects the middle age and elderly population, but it has been observed in young adults too. Dr. Naveen Pemmaraju, a specialist at The University of Texas MD Anderson Cancer Center, explains what treatment options are available and how the livelihoods of youth are affected. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features Drs. Howard J. Burstein and Kimberly L. Blackwell discussing practical aspects of using this class of agents as first-line therapy in HR+/HER2- advanced or…

In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute contextualizes updates to the standard of care, relays the latest developments in immunotherapy, and offers insight into best practices for the incorporation of novel agents in your clinical practice. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7265 © 2017 Imedex, LLC.

In this Velocity Vlog activity, Dr. Paul Nghiem of the University of Washington shares emerging data and expert analysis about diagnosis, the emergence of immunotherapy as a viable therapeutic option, and the evolving standard of care for MCC. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7264 © 2017 Imedex, LLC.

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features Drs. Howard J. Burstein and Joyce O’Shaughnessy discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic…

Dr. Jack West reviews new evidence providing long-needed guidance on what patient surveillance after potentially curative surgery for early lung cancer makes a difference. The IFCT-0302 trial tests a minimal vs. maximal approach to answer that question.

Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.

How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase? Physician assistant, Lindsey Kalhagen, discusses progression and what might indicate a need for an adjustment in treatment. Although it can be difficult to differentiate side effects from medications and symptoms, its important for patients to monitor physical changes that could signify disease progression. Watch now to learn how paying close attention to symptoms, observing changes, and communicating with your provider can improve outcomes. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on…

Scott S. Tykodi MD of Seattle Cancer Care Alliance notes that the data from Checkmate 214 is clear that overall high grade side effects are better with immunotherapy.

Michael Needle, MD and Chief Medical Officer for AVEO Oncology gives an update for the Phase 3 TIVO-3 trial, a randomized, controlled,multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than immunotherapy treatments.

Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in 2014. On August 28, 2017 it was announces that Tivozanib (FOTIVDA®) has been approved in the EU for RCC patients.

Dr. Scott S. Tykodi, MD reveals the results of the Checkmate – 214 trial with combined immunotherapy nivolumab plus ipilimumab and explains the positive results on objective response rate and prolonged progression-free survival compared to sunitinib in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.

Michael Needle, MD and Chief Medical Officer of AVEO Oncology goes over why and how Tivozanib (FOTIVDA(R)) was given approval in the European Union for the treatment of advanced renal cell carcinoma.

K. Robert Shen, MD of of the Mayo Clinic in Rochester, MN discusses what to do with an esophageal cancer patient. When to use surgery versus induction therapy?